Introduction
============

Pharmacogenomics studies the interaction between the genome and drugs on their way through the human body. To achieve their therapeutic role, drugs interact with multiple substances, such as enzymes. DNA polymorphisms may affect genes coding for enzymes in terms of quality or quantity of the enzyme produced. Thus, DNA polymorphisms may have an impact on the metabolism of drugs, especially chemotherapy. As the majority of chemotherapeutic agents have a narrow therapeutic range, even small defects in their metabolism may affect toxicity.

Irinotecan is an example of the above situation. Irinotecan is metabolised by carboxylesterases to form its active metabolite, SN-38. This is further glucuronated in the liver by glucuronosyltransferases and it forms the inactive metabolite SN-38G, which is eliminated mainly via the bile into the intestine. In the intestine, SN-38G is deconjucated back to SN-38 by bacterial β-glucuronidases. SN-38 is reabsorbed in the systemic circulation (enterohepatic circulation of SN-38). Glucuronosyltransferases expressed in the gut play a role in the reglucuronidation and detoxification of SN-38 in the intestine. The glucuronosyltransferase *UGT1A1*, which is primarily responsible for the glucuronidation of SN-38 in the liver, is also responsible for the conversion of indirect to direct bilirubin. Polymorphisms of the gene encoding *UGT1A1* may lead to reduced enzyme expression and reduced catalytic activity. *UGT1A1\*28* polymorphism is about a TA insertion in the TATA box of the promoter of the gene (seven instead of six TA repeats), (TA)7 instead of (TA)6 *UGT1A1\*1*. The elongated TATA box in the promoter region results in reduced gene expression of about 30%. Approximately 10% of Caucasians are homozygous *UGT1A1\*28*/*UGT1A1\*28* \[(TA)~7~/(TA)~7~\] for this polymorphism which leads to Gilbert's syndrome. These patients cannot glucuronate indirect to direct bilirubin sufficiently and may present with mild indirect hyperbilirubinemia. These patients, for the same reason, have a reduced glucuronidation of SN-38, and thus a higher exposure to the active metabolite. This exposure has been linked to higher toxicity of irinotecan \[[@ref1]--[@ref4]\]. Polymorphisms of the gene encoding the extra hepatic glucuronosyltransferase *UGT1A7*, such as *UGT1A7\*2* and *UGT1A7\*3*, may also lead to elevated toxicity due to reduced reglucuronidation of SN-38 in the intestine \[[@ref5], [@ref6]\]. Eighty-seven per cent of Caucasians carry at least one of the *UGT1A7\*2*, *UGT1A7\*3*, and *UGT1A7\*4* polymorphisms, the last being rather rare \[[@ref7]\].

Since 2005, the US Food and Drug Administration (FDA) has recommended that a reduced initial dose of irinotecan should be considered for patients known to be homozygous for the *UGT1A1\*28* allele, because they are at increased risk for neutropenia following irinotecan treatment. However, genotyping for irinotecan toxicity has not been put into routine clinical practice. Furthermore, several studies failed to demonstrate any significant relationship between these *UGT* polymorphisms and irinotecan toxicity \[[@ref8]--[@ref11]\], and a meta-analysis concluded that the risk of toxicity was similar for patients with all genotypes at low doses of the drug \[[@ref12]\]. In 2010, another meta-analysis concluded that *UGT1A1\*28*/\*28 genotype was associated with an increased risk of neutropenia in low doses as well. Moreover, it associated the homozygous and the heterozygous genotype with the risk of severe diarrhoea at medium and high doses \[[@ref13], [@ref14]\]. A recent meta-analysis showed that homozygous and heterozygous patients were at increased risk of neutropenia regardless of the dose of irinotecan administered. Homozygous patients were also at increased risk of diarrhoea when receiving medium or high doses, but not low doses, of the drug \[[@ref15]\]. These results confirm the need for further studies, to determine the optimal dose for each patient and the need for genotyping.

Our purpose was to examine the association between irinotecan toxicity and *UGT1A1\*28*, *UGT1A7\*2*, and *UGT1A7\*3* polymorphisms in Greek patients with colorectal cancer receiving low-dose irinotecan treatment. These polymorphisms were selected for analysis as their prevalence is high among Caucasians and the results of previous studies were inconclusive. Information of this type, to the best of our knowledge, is lacking for Greek subjects.

Patients and methods
====================

Forty-six patients (23 male and 23 female) were studied from January 2009 to July 2012. Patients were eligible if they suffered from metastatic colorectal cancer treated with irinotecan--leucovorin--5-FU. The median age was 62.3 years (range: 33--78). Thirty-nine patients (84.8%) had performance status (Karnofsky) 70--90%, and seven (15.2%) 100%. The primary tumour site was the colon in 41 patients (89.1%), the rectum in four (8.7%), and unknown in one patient. The primary tumour was resected in 43 patients (93.5%) ([Table 1](#table1){ref-type="table"}).

All of them received, according to Gennatas *et al* \[[@ref16]\], irinotecan 80 mg/m^2^ (30--90 min IV infusion), followed by leucovorin 200 mg/m^2^ bolus IV and 5-fluorouracil 450 mg/m^2^ bolus IV on days 1, 8, 15, 22, 29, 36, and every eight weeks. Treatment was discontinued in progression or intolerable toxicity. Before treatment, patients received atropine 0.5 mg SC to prevent cholinergic syndrome and ondansetron 8 mg IV to prevent vomiting. Ondansetron and loperamide were prescribed, incase of vomiting and diarrhoea. G-CSF was used for the treatment of neutropenia and as prophylaxis when it was considered necessary to maintain chemotherapy, according to the EORTC guidelines. Treatment was postponed until recovery in cases of grade ≥1 haematologic toxicity and diarrhoea as well as in cases of any other toxicity of grade ≥2 (except alopecia). In cases of grade 3--4 toxicity the irinotecan dose was reduced by 20% and in the recurrence of toxicity a second dose reduction by 20% was decided. Patients were evaluated with physical examination and laboratory tests before each treatment. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. The research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions. The protocol of the study was approved by the ethics committee of the participating institution and all patients gave written informed consent.

Peripheral blood was collected and DNA was extracted using the QIAamp DNA Blood midi kit (Qiagen GmbH, Hilden, Germany). *UGT1A1* genotyping was performed by means of PCR using primers F1: 5′CTTGGTGTATCGATTGGTTTTTG3′ and R1: 5′ TTTGCTCCTGCCAGAGGTTCG3′. The amplicons were resolved on 12% polyacrylamide gel electrophoresis. Two different fragment sizes were revealed depending on the number of (TA) repeats. A 71-bp fragment contained the (TA)6 motif assigned as *UGT1A1\*1* and a 73-bp fragment contained the (TA)7 motif assigned as *UGT1A1\*28*. *UGT1A7* genotyping was performed on exon 1 by means of PCR. A 415-bp fragment was amplified using primers F2: 5′TTTGCCGATGCTCGCTGGACG3′ and R2: 5′GCTATTTCTAAGACATTTTTGAAAAAATAGGG3′. Direct sequencing was performed on the resulting product that spans the informative polymorphic sites, namely G115S, N129K, R131K, W208R, and E139D. Genotypes were assigned as *UGT1A7\*1* (G115, N129, R131, and W208), *UGT1A7\*2* (K129 and K131), *UGT1A7\*3* (K129, K131, and R208), and *UGT1A7\*4* (R208).

Associations between genotypes of *UGT1A1*, *UGT1A7*, and baseline patients' characteristics (age, sex, performance status, primary tumour site, previous chemotherapy, and metastatic sites) as well as with toxicities, dose delays, and dose reductions were investigated by chi-squared statistic with continuity correction. Ninety-five per cent confidence intervals for proportions indicating the magnitude of association are presented in case of statistically significant results. Evaluation of any toxicities, dose delays and dose reductions was based on the incidence of the event occurred upon the total weeks of treatment. One-way analysis of variance (ANOVA) was employed to investigate differences between the genotypes and laboratory parameters as transformed in logarithmic scale when needed. All tests were two-sided and the level of statistical significance was set at 5%.

Results
=======

*UGT1A1* genotyping revealed 22/46 patients (47.8%) as homozygotes *UGT1A1\*1/\*1*, 20/46 patients (43.5%) as heterozygotes *UGT1A1\*1/\*28*, and 4/46 patients (8.7%) as homozygotes for *UGT1A1\*28/\*28*. *UGT1A7* genotyping revealed the following genotypes with the equivalent frequencies, *UGT1A7\*1/\*1* 4/46 (8.7%), *UGT1A7\*1/\*2* 12/46 (26.1%), *UGT1A7\*1/\*3* 15/46 (32.6%), *UGT1A7\*1/\*4* 1/46 (2.2%), *UGT1A7\*2/\*2* 3/46 (6.5%), *UGT1A7\*2/\*3* 7/46 (15.2%), and *UGT1A7\*3/\*3* 4/46 (8.7%) ([Table 2](#table2){ref-type="table"}).

We considered serious toxicity, toxicity of grade ≥3 according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Patients heterozygous for the *UGT1A1\*28* polymorphism, *UGT1A1\*1/\*28*, had significantly higher incidence of leucocytopenia (*p* = 0.0002), neutropenia (*p* = 0.0146), thrombocytopenia (*p* = 0.0032), febrile neutropenia (*p* = 0.0002), and overall haematologic toxicity (*p* \< 0.00001), than those with *UGT1A1\*1/\*1* and *UGT1A1\*28/\*28* genotype. Homozygous *UGT1A1\*28/\*28* patients experienced haematologic toxicity, especially leucocytopenia and neutropenia, but because of the few events analysed the results were not statistically significant. The incidence of anaemia did not correlate with genotype. As far as non-haematologic toxicity is concerned, patients *UGT1A1\*1/\*28* and *UGT1A1\*28/\*28* had significantly higher incidence of both diarrhoea and total non-haematologic toxicity than *UGT1A1\*1/\*1* patients (*p* = 0.0002 and *p* = 0.02204, respectively) ([Table 3](#table3){ref-type="table"}).

Apart from *UGT1A1\*28*, *UGT1A7\*2*, and *UGT1A7\*3* were studied. One patient carried the rare allele *UGT1A7\*4*. Regarding haematologic toxicity there was significant difference between genotypes who experienced, *UGT1A7\*1/\*3*, *UGT1A7\*2/\*3*, *UGT1A7\*3/\*3*, and those who did not experience, *UGT1A7\*1/\*4* and *UGT1A7\*2/\*2*, toxicity. Moreover, genotype *UGT1A7\*1/\*3* had a significantly higher incidence of toxicity than genotypes *UGT1A7\*1/\*1* and *UGT1A7\*1/\*2* (*p* = 0.0005). Concerning non-haematologic toxicity there was again significant difference between genotypes who experienced, *UGT1A7\*1/\*2*, *UGT1A7\*1/\*3*, *UGT1A7\*2/\*3*, *UGT1A7\*3/\*3*, and those who did not experience, *UGT1A7\*1/\*1*, *UGT1A7\*1/\*4*, *UGT1A7\*2/\*2*, toxicity (*p* = 0.00702) ([Table 4](#table4){ref-type="table"}).

Dose delays and dose reductions had no significant association with genotypes.

Genotype *UGT1A1\*28/\*28* had significantly higher mean ( *p* = 0.043) and maximum ( *p* = 0.034) bilirubin rates during the entire course of therapy than *UGT1A1\*1/\*28* and *UGT1A1\*1/\*1*, as it was expected. Data were transformed into logarithms and geometric means were 1.15 (95% confidence interval \[0.17--7.54\]) and 1.90 (95% confidence interval \[0.21--17.50\]), respectively.

Patients with haematologic toxicity only, had significantly lower baseline and mean haemoglobin (*p* = 0.003 and *p* = 0.023, respectively) as compared with all other cases.

Discussion
==========

The purpose of this study was to investigate whether *UGT1A1* and *UGT1A7* genotypes, more common in Caucasians, correlate with irinotecan toxicity, even at low doses of the drug (80 mg/m^2^).

Our results show that in our population the presence of *UGT1A1\*28* polymorphism was associated with both haematologic and non-haematologic toxicity. Heterozygous *UGT1A1\*1/\*28* patients encountered significant haematologic and non-haematologic toxicity in accordance with the results of previous studies, which correlated *UGT1A1\*1/\*28* genotype with toxicity \[[@ref1], [@ref2]\]. As far as it concerns homozygous *UGT1A1\*28/\*28* patients, they experienced significant non-haematologic toxicity, especially diarrhoea. Moreover, *UGT1A1\*28/\*28* patients experienced leucocytopenia and neutropenia, although this is not statistically significant, probably due to the small number of the events analysed, as we only had four homozygous patients.

The first studies published on this subject led to the FDA recommendation on the dose recommended to *UGT1A1\*28/\*28* patients. However, conflicting results from subsequent studies are opposing such genotyping in clinical practice. Lankisch *et al* \[[@ref5]\] did not correlate *UGT1A1\*28* polymorphism with toxicity in patients receiving low-dose irinotecan regimens (80 mg/m^2^/wk). Schulz *et al* \[[@ref9]\] mentioned no significant effect of *UGT1A1\*28* polymorphism on irinotecan toxicity in patients treated with low-dose irinotecan (80 mg/m^2^/wk, modified FOLFIRI -- modified IROX) as well. In a meta-analysis, Hoskins *et al* \[[@ref12]\] concluded that the risk of toxicity was not statistically different between *UGT1A1\*28/\*28* and *UGT1A1\*1/\*1* at low irinotecan doses and patients receiving lower doses should not be genotyped. Deeken *et al* \[[@ref17]\] suggested commencing therapy at higher doses for a better response and dose reduction if toxicity appeared. On the other hand, Toffoli *et al* \[[@ref18]\] showed that the recommended dose of irinotecan in FOLFIRI (180 mg/m^2^) is lower than the one that can be tolerated by *UGT1A1\*1/\*1* and *UGT1A1\*1/\*28* patients. This poses the question whether higher doses confer a survival advantage to patients. However, Toffoli *et al* \[[@ref18]\] did not study *UGT1A1\*28/\*28* patients.

Our results for *UGT1A7* polymorphisms correlate them, and especially *UGT1A7\*3*, with both haematologic and non-haematologic toxicity, as patients carrying the *UGT1A7\*3* allele seemed to have higher incidence of toxicity. Cecchin *et al* \[[@ref6]\] in agreement to our results, concluded that *UGT1A7\*3/\*3* genotype is the only predictive marker of severe haematologic toxicity after the first cycle of chemotherapy. *UGT1A7\*3* interference with non-haematologic toxicity is referred by Martinez-Balibrea *et al* \[[@ref4]\] correlating *UGT1A7\*3/\*3* genotype with higher risk of severe diarrhoea at the end of the first cycle of chemotherapy. We therefore propose that results for *UGT1A1\*28*, *UGT1A7\*2*, and *UGT1A7\*3* alleles, indicate that they may be used as useful markers for predicting haematologic and non-haematologic toxicity in irinotecan treated patients.

Apart from genetic factors altering the drug metabolism, it is possible that epigenetic changes in colon cancer cells play a role in the expression of *UGT*s and the metabolism of irinotecan by the tumour, influencing treatment toxicity and efficacy \[[@ref19]\]. Moreover, DNA methylation at selected CpG sites in the promoter region of the *UGT1A1* gene, in liver, may influence the catalytic activity of the underlying enzyme \[[@ref20]\].

We would also like to note that irinotecan is given in combination with 5-FU, which is a drug that may also cause haematologic and gastrointestinal toxicity. There is, therefore, a possibility that 5-FU may play a role in toxicity.

Dose delays and dose reductions did not show any association with genotypes despite the fact that they indirectly refer to toxicity. Other factors such as performance status, age, sex, primary tumour resection, previous chemotherapy, and metastatic sites were analysed and did not have any association with toxicity or genotype. Patients who suffered from haematologic toxicity had lower baseline and mean haemoglobin. None of the other basic laboratory tests had any association with toxicity. Homozygous *UGT1A1\*28*/\*28 patients had significantly higher mean and maximum bilirubin rates, but no other biochemical marker had any correlation with genotype.

We did not conduct linkage disequilibrium analysis as Kohle *et al* \[[@ref21]\] has already showed frequent co-occurrence of *UGT1A1\*28* and *UGT1A7\*3* alleles. Nevertheless, we would like to note that three out of four *UGT1A1\*28*/\*28 patients in our sample were also *UGT1A7\*3/\*3*.

According to the results of the present study, we propose *UGT* genotyping, especially for *UGT1A1\*28*, *UGT1A7\*2*, and *UGT1A7\*3* alleles in all patients, regardless dose, as even low doses (80 mg/m^2^) of irinotecan may increase toxicity. Genotyping can help in personalising patient's management thus reducing toxicity and subsequent financial costs (antibiotics and growth factors). Further studies are needed in optimising the dose for each individual.

Conclusions
===========

Despite previous studies \[[@ref5], [@ref9], [@ref12]\], our results show that irinotecan, even in low doses, can cause serious toxicity in patients carrying *UGT* polymorphisms. However, some ten years after the first reports on the role of *UGT*s on irinotecan toxicity, many questions remain to be answered. New, larger studies are needed before utilising this knowledge in everyday practice.

The study was funded by the Special Account for Research Grants, National and Kapodistrian University of Athens.

###### Patients' characteristics.

  Characteristics                  Number of patients   \%
  -------------------------------- -------------------- ------
  Sex                                                   
  Male                             23                   50
  Female                           23                   50
  Age                                                   
  Median                           62.3                 
  Range                            33--78               
  Performance Status (Karnofsky)                        
  70--90%                          39                   84.8
  100%                             7                    15.2
  Primary site                                          
  Colon                            41                   89.1
  Rectum                           4                    8.7
  Unknown                          1                    2.2
  Primary tumour resected                               
  Yes                              43                   93.5
  No                               3                    6.5

###### Genotype frequencies.

  Genotype            Number of patients   \%
  ------------------- -------------------- ------
  *UGT1A1*                                 
  *UGT1A1\*1/\*1*     22                   47.8
  *UGT1A1\*1/\*28*    20                   43.5
  *UGT1A1\*28/\*28*   4                    8.7
  *UGT1A7*                                 
  *UGT1A7\*1/\*1*     4                    8.7
  *UGT1A7\*1/\*2*     12                   26.1
  *UGT1A7\*1/\*3*     15                   32.6
  *UGT1A7\*1/\*4*     1                    2.2
  *UGT1A7\*2/\*2*     3                    6.5
  *UGT1A7\*2/\*3*     7                    15.2
  *UGT1A7\*3/\*3*     4                    8.7

###### Correlation of *UGT1A1\*28* with toxicity (haematologic and non-haematologic).

  Haematologic toxicity (Feb.Neut./Hb/WBC/Neu/Plts)[\*](#table03-fn1){ref-type="table-fn"}                                                                   
  ------------------------------------------------------------------------------------------ ------------- -------------- ------------ -------------- ------ ------------------
  **Genotype**                                                                               *\*1/\*1*     579 (98.3%)    10 (1.7%)    0.93--3.09%    589    \<0.00001
                                                                                             *\*1/\*28*    347 (87.4%)    50 (12.6%)   9.69--16.22%   397    *X*^2^ = 55.024,
                                                                                             *\*28/\*28*   97 (98.0%)     2 (2.0%)     0.62--7.04%    99     df = 2
  **Overall**                                                                                              1023 (94.3%)   62 (5.7%)                   1085   

  Non-haematologic toxicity (diarrhoea/vomiting/nausea)                                                                  
  ------------------------------------------------------- ------------- -------------- ----------- -------------- ------ ----------------
  **Genotype**                                            *\*1/\*1*     564 (95.8%)    25 (4.2%)   2.90--6.20%    589    0.02204
                                                          *\*1/\*28*    364 (91.7%)    33 (8.3%)   5.99--11.45%   397    *X*^2^ = 7.63,
                                                          *\*28/\*28*   91 (91.9%)     8 (8.1%)    4.20--15.16%   99     df = 2
  **Overall**                                                           1019 (94.9%)   66 (5.1%)                  1085   

Haematologic toxicity (febrile neutropenia/haemoglobin/white blood cells/platelets).

Grade 0--2 events.

Grade 3--4 events.

95% confidence interval grade 3--4.

Weeks of therapy.

###### Correlation of *UGT1A7\*2* and *UGT1A7\*3* with toxicity (haematologic and non-haematologic).

  Haematologic toxicity (Feb.Neut./Hb/WBC/Neu/Plts)[\*](#table04-fn1){ref-type="table-fn"}                                                               
  ------------------------------------------------------------------------------------------ ----------- ------------- ----------- -------------- ------ ------------------
  **Genotype**                                                                               *\*1/\*1*   109 (98.2%)   2 (1.8%)    0.56--6.30%    111    0.0005
                                                                                             *\*1/\*2*   290 (96.0%)   12 (4.0%)   2.30--6.82%    302    *X*^2^ = 24.083,
                                                                                             *\*1/\*3*   294 (90.5%)   31 (9.5%)   6.81--13.23%   325    df = 6
                                                                                             *\*1/\*4*   32 (100.0%)   0                          32     
                                                                                             *\*2/\*2*   60 (100.0%)   0                          60     
                                                                                             *\*2/\*3*   155 (91.2%)   15 (8.8%)   5.44--14.06%   170    
                                                                                             *\*3/\*3*   83 (97.6%)    2 (2.4%)    0.73--8.15%    85     
  **Overall**                                                                                            1023          62                         1085   

  Non-haematologic toxicity (diarrhoea/vomiting/nausea)                                                                
  ------------------------------------------------------- ----------- -------------- ----------- -------------- ------ ------------------
  **Genotype**                                            *\*1/\*1*   111 (100.0%)   0 (0.0%)                   111    0.00702
                                                          *\*1/\*2*   281 (93.0%)    21 (7.0%)   4.61--10.40%   302    *X*^2^ = 17.701,
                                                          *\*1/\*3*   303 (93.2%)    22 (6.8%)   4.53--10.04%   325    df = 6
                                                          *\*1/\*4*   32 (100.0%)    0 (0.0%)                   32     
                                                          *\*2/\*2*   60 (100.0%)    0 (0.0%)                   60     
                                                          *\*2/\*3*   155 (91.2%)    15 (8.8%)   5.44--14.06%   170    
                                                          *\*3/\*3*   77 (0.6%)      8 (9.4%)    4.90--17.51%   85     
  **Overall**                                                         1019           66                         1085   

Haematologic toxicity (febrile neutropenia/haemoglobin/white blood cells/platelets).

Grade 0--2 events.

Grade 3--4 events.

95% confidence interval grade 3--4.

Weeks of therapy.
